No changes in efavirenz plasma concentrations in HIV-infected patients who switch from Stocrin to Atripla.
Burger
David
D
van Luin
Matthijs
M
Bosch
Marjolein
M
van der Ven
Andre
A
Brouwer
Anne-Marie
AM
Keuter
Monique
M
Dofferhoff
Ton
T
Koopmans
Peter P
PP
D000225:Adenine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D000480:Alkynes; D019380:Anti-HIV Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D048588:Benzoxazines / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D003521:Cyclopropanes; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D004338:Drug Combinations; D000068257:Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; D015658:HIV Infections / Q000188:drug therapy; D006801:Humans; D063065:Organophosphonates / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D010078:Oxazines / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D010949:Plasma / Q000737:chemistry*
D000480:Alkynes; D019380:Anti-HIV Agents; D048588:Benzoxazines; D003521:Cyclopropanes; D004338:Drug Combinations; D000068257:Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; D063065:Organophosphonates; D010078:Oxazines; D003841:Deoxycytidine; D000225:Adenine; C098320:efavirenz